Shanghai RAAS Blood Products Co (002252) Fair Value & Analysis
Healthcare · CN · Market cap 31.6B CNY
Fair value as of: Jul 22, 2026
From 17 valuation models · updated 19 days ago
Fair value updated Jul 22, 2026, revised from ¥4.54 to ¥4.18 (−7.9%) since Jun 25, 2026. Share price +12.8% over the past month.
A solid business, but screening 17% overvalued on our models.
What matters now
- Solid but not exceptional quality (51/100) and above fair value, neither a clear bargain nor a standout compounder.
- Our model range runs from ¥3.05 (bear) to ¥5.32 (bull), base ¥4.18. The closer the price sits to the lower half, the larger the margin of safety.
- Quality 51/100 (solid quality) with high evidence: the data supports the verdict.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 22, 2026.
How to read this chart
60‑month range ¥4.31 – ¥8.33 · fair‑value band ¥3.05 – ¥5.32 · the ¥5.04 price screens above the ¥4.18 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jul 22, 2026.
Analysis
Shanghai RAAS Blood Products Co (002252) currently trades at ¥5.04, while our model-based Fair Value estimate is ¥4.18, implying the stock looks roughly 17.1% overvalued today. The Quality Score stands at 51/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).
Over the trailing twelve months, Shanghai RAAS Blood Products Co generated revenue of 6.9B CNY at a net margin of 19.4%. Revenue declined 24.7% year over year. It earns a return on equity of 4.1%. Net debt stands at 2.6B CNY. Fundamentals as of Jul 22, 2026
Our scenario range runs from ¥3.05 (bear case) to ¥5.32 (bull case); at ¥5.04, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 30% below its 52-week high and 7% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -43% fair-value upside, at -17%, 002252 screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 17 models by family
Widest divergence: DCF Models (¥7.43) versus Dividend Discount (¥0.7800). Highest evidence: Residual Income (76).
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 22, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 48 · Market factors (momentum, volatility) 36
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Shanghai RAAS Blood Products Co., Ltd., together with its subsidiaries, produces and sells blood products in China and internationally.
Full company description
Shanghai RAAS Blood Products Co., Ltd., together with its subsidiaries, produces and sells blood products in China and internationally. The company offers ALBURAAS, which is albumin prepared from human plasma; GAMARAAS, a human immunoglobulin product for intravenous injections; HEMORAAS, a human coagulation factor VIII product; PROTHORAAS, a human prothrombin complex; FIBRORAAS, a human fibrinogen; FIBINGLURAAS, a fibrin sealant for humans; and THROMBIRAAS, a human thrombin product. It also provides specific immune, human tetanus immunoglobulin, human rabies immunoglobulin, human immunoglobulin, hepatitis B human immunoglobulin, and other blood products. The company exports its products. Shanghai RAAS Blood Products Co., Ltd. was founded in 1988 and is headquartered in Shanghai, China.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Shanghai RAAS Blood Products Co reported revenue of ¥7.3B in FY2025 versus ¥4.3B in FY2021, a compound +14.4%/yr. Reported net income was ¥1.6B in FY2025, compounding +5.1%/yr from FY2021.
002252 screens 17% overvalued. Compare with Vertex Pharmaceuticals Incorporated →
Peer Group
Biotechnology · 603 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Biotechnology median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Jul 22, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX | $486.03 | $278.78 | -43% |
| Regeneron Pharmaceuticals, Inc REGN | $664.45 | $594.40 | -11% |
| Samsung Biologics Co 207940 | 1,368,000 KRW | 1,091,384 KRW | -20% |
| Celltrion, Inc 068270 | 175,800 KRW | 76,325 KRW | -57% |
| WuXi Biologics (Cayman) Inc 2269 | HK$39.54 | HK$30.42 | -23% |
| Innovent Biologics, Inc 1801 | HK$86.70 | HK$19.66 | -77% |
| Sino Biopharmaceutical Limited 1177 | HK$5.26 | HK$3.36 | -36% |
| ALTEOGEN Inc 196170 | 276,500 KRW | 44,444 KRW | -84% |
| RemeGen Co 688331 | ¥134.02 | ¥26.99 | -80% |
| Biocon Limited BIOCON | ₹440.70 | ₹57.36 | -87% |
Compare Shanghai RAAS Blood Products Co with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Shanghai RAAS Blood Products Co (002252) overvalued or undervalued?
What is the fair value of 002252?
What is the quality score of 002252?
What is the revenue of Shanghai RAAS Blood Products Co (002252)?
What is the net profit margin of 002252?
Does Shanghai RAAS Blood Products Co pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Shanghai RAAS Blood Products Co and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.